DHL Global Forwarding has advanced its cold chain logistics offerings in Asia Pacific through the inauguration of a cutting-edge pharmaceutical facility at Kuala Lumpur International Airport (KLIA). This strategic move not only solidifies DHL’s position as a prominent player in healthcare logistics but also caters to the escalating need for temperature-sensitive pharmaceutical transportation in the region. The newly established 38,000-square-foot facility, situated in KLIA’s Free Commercial Zone, is a dual-certified site for both 15–25°C and 2–8°C storage, providing enhanced flexibility for pharmaceutical, biologics, and vaccine manufacturers and distributors.
The facility at KLIA underscores DHL’s commitment to expanding its pharma supply chain infrastructure, featuring specialized cold rooms, secure storage units with restricted access, automated environmental monitoring systems, and reefer truck transfers to uphold product integrity throughout the transportation process. By obtaining both IATA CEIV Pharma certification and DHL’s Air GxP certification, the hub ensures strict compliance with the industry’s most rigorous standards while incorporating sustainability practices like energy-efficient compressors and environmentally friendly refrigerants.
Praveen Gregory, the Managing Director for Singapore, Malaysia, and Brunei at DHL Global Forwarding, highlights Malaysia’s strategic positioning as a regional hub for global medical technology companies, with the market projected to reach $4.5 billion by 2028. The state-of-the-art cold chain infrastructure at KLIA has been consistently delivering exceptional standards in pharmaceutical logistics since 2023 and is well-equipped to meet the escalating demand across Asia Pacific with top-notch facilities and expertise.
As the healthcare logistics market in Asia Pacific continues to expand rapidly, research indicates substantial growth from $17.6 billion in 2022 to $29.5 billion by 2030, driven by factors such as aging populations, increasing prevalence of chronic diseases, and a growing need for vaccines and biologics. DHL’s extensive network of 37 Air GxP-certified stations and 12 IATA CEIV Pharma-certified facilities across the region, including key locations like Singapore, Tokyo, and Shanghai, positions the company at the forefront of this burgeoning trend, with the new KLIA facility further enhancing Malaysia’s significance in the global healthcare supply chain.
Aligned with DHL Group’s Strategy 2030: Accelerating Sustainable Growth, which identifies Life Sciences and Healthcare as a key growth sector, the investment in the KLIA facility underscores the company’s commitment to providing state-of-the-art logistics solutions. This not only enhances capacity but also ensures the seamless, secure, and sustainable movement of critical healthcare products across borders. Amidst the relentless demand for temperature-controlled logistics in Asia Pacific, DHL’s recent infrastructure investment exemplifies the race among global forwarders to establish a strong foothold in one of the world’s fastest-growing healthcare markets.
Key Takeaways:
– DHL’s new dual-certified pharmaceutical facility at KLIA strengthens its cold chain logistics capabilities in Asia Pacific, catering to the escalating demand for temperature-sensitive pharmaceutical transportation.
– The facility, equipped with advanced features and sustainability measures, underscores DHL’s commitment to providing top-notch pharmaceutical logistics services and ensuring compliance with industry standards.
– Positioned strategically in Malaysia, the hub aligns with DHL’s focus on the region’s growing healthcare logistics market, supported by a network of certified facilities across key locations in Asia Pacific.
– The investment in the KLIA facility reflects DHL’s dedication to meeting the evolving needs of the healthcare sector, emphasizing secure and sustainable logistics solutions for critical healthcare products.
Tags: cold chain logistics, environmental monitoring
Read more on freightwaves.com